医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline in the Class Action Lawsuit Against Impax Laboratories, Inc.

2014年10月06日 PM11:32
このエントリーをはてなブックマークに追加


 

BENSALEM, Pa.

Law Offices of Howard G. Smith reminds investors that purchasers of the securities of Impax Laboratories, Inc. (“Impax” or the “Company”) (NASDAQ:IPXL) between May 20, 2013 and July 28, 2014, inclusive (the “Class Period”), have until October 14, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Impax develops, manufactures and markets bioequivalent pharmaceutical products, and develops and markets branded products. The Company currently has one late-stage branded pharmaceutical product candidate being developed internally, RYTARY™ (IPX066), an extended-release capsule formulation of carbidopa-levodopa for the symptomatic treatment of Parkinson’s disease.

The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding quality control matters at the Company’s Taiwan production facility. Specifically, defendants misrepresented and/or failed to disclose that: (1) the Company failed to maintain proper quality control and manufacturing practices at its Taiwan facility in violation of current Good Manufacturing Practices; (2) the manufacturing deficiencies at the Taiwan facility could have a material adverse impact on the Company’s ability to successfully launch RYTARY, and jeopardized the Company’s ability to manufacture, sell, and distribute generic pharmaceutical products; and (3), based on the foregoing, defendants lacked a reasonable basis for their positive statements about the Company and its outlook, including statements about its ability to launch RYTARY.

If you are a member of the Class described above, you may move the Court no later than October 14, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.

CONTACT

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent